Current Report Filing (8-k)
10 December 2020 - 12:31AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
December 8, 2020
ARMATA
PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in
its charter)
Washington
|
001-37544
|
91-1549568
|
(State or other jurisdiction of incorporation or organization)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
4503 Glencoe Avenue
Marina del Rey, California
|
90292
|
(Address of principal executive offices)
|
(Zip Code)
|
(310) 655-2928
(Registrant’s Telephone number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of
the Act:
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which Registered
|
Common Stock
|
|
ARMP
|
|
NYSE American
|
|
Item 5.07
|
Submission of Matters to a Vote of Security Holders.
|
Armata Pharmaceuticals, Inc. (the “Company”)
held its annual meeting of stockholders (the “Annual Meeting”) on December 8, 2020, at 8:30 a.m. local time
at the Company’s headquarters in Marina del Rey, California. At the Annual Meeting, stockholders voted on the matters disclosed
in the Company's definitive proxy statement filed with the Securities and Exchange Commission on October 22, 2020. The final voting
results for the matters submitted to a vote of stockholders are provided below
Proposal 1 – Election of directors:
All of the Company’s director nominees were elected for
a one-year term expiring at the 2021 Annual Meeting of Shareholders.
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
Todd R. Patrick
|
12,837,561
|
|
13,793
|
|
1,124,364
|
Richard J. Bastiani, Ph.D.
|
12,836,461
|
|
14,893
|
|
1,124,364
|
Sarah J. Schlesinger, M.D.
|
12,825,302
|
|
26,052
|
|
1,124,364
|
Joseph M. Patti, Ph.D.
|
12,837,567
|
|
13,787
|
|
1,124,364
|
Odysseas D. Kostas, M.D.
|
12,838,367
|
|
12,987
|
|
1,124,364
|
Todd C. Peterson, Ph.D.
|
12,837,656
|
|
13,698
|
|
1,124,364
|
Robin C. Kramer
|
12,838,383
|
|
12,971
|
|
1,124,364
|
Proposal 2 – Advisory, non-binding vote on executive
compensation:
The Company’s stockholders approved, on an advisory, non-binding
basis, the Company’s executive officer compensation.
Vote For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
12,771,720
|
|
32,726
|
|
46,908
|
|
1,124,364
|
Proposal 3 – Non-binding advisory approval of the
frequency of future advisory votes on the Company's named executive officer compensation:
The Company's stockholders approved, on an advisory basis, a
one-year frequency for future advisory votes on the Company's named executive officer compensation.
1 Year
|
|
2 Years
|
|
3 Years
|
|
Abstentions
|
|
Broker Non-Votes
|
11,704,578
|
|
899,965
|
|
224,260
|
|
22,551
|
|
1,124,364
|
After considering the results of the non-binding advisory vote
on the frequency of future advisory votes on the Company’s named executive officer compensation at the Annual Meeting, the
Company’s Board of Directors determined that the Company will hold an advisory vote on named executive compensation annually
until the next required vote on the frequency of such votes.
Proposal 4 — Ratification of selection of Ernst
& Young LLP as the independent registered public accounting firm:
The Company's stockholders ratified the appointment of Ernst
& Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020.
Vote For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
13,948,254
|
|
8,904
|
|
18,560
|
|
0
|
On December 9, 2020, the Company issued a press release announcing
the election of Robin C. Kramer to its Board of Directors. Following the Annual Meeting, the Board appointed Robin C. Kramer was
appointed to serve as a director and as Chair of the Audit Committee.
The full text of the press release issued in connection with
this announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 9, 2020
|
Armata Pharmaceuticals, Inc.
|
|
|
|
By:
|
/s/ Steve R. Martin
|
|
Name:
|
Steve R. Martin
|
|
Title:
|
Chief Financial Officer
|
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From Apr 2024 to May 2024
Armata Pharmaceuticals (AMEX:ARMP)
Historical Stock Chart
From May 2023 to May 2024